| Placebo (N = 20) | Eclitasertib 600 mg (N = 47) | All (N = 67) |
---|---|---|---|
Age (years), mean (SD) | 55.2 (13.5) | 58.9 (11.3) | 57.8 (12.0) |
Sex, n(%) | Â | Â | Â |
 Male / Female | 12 (60.0)/ 8 (40.0) | 28 (59.6)/ 19 (40.4) | 40 (59.7)/ 27 (40.3) |
Race, n(%) | Â | Â | Â |
 White | 16 (80.0) | 40 (85.1) | 56 (83.6) |
 Black or African American | 2 (10.0) | 3 (6.4) | 5 (7.5) |
 American Indian or Alaska Native | 1 (5.0) | 1 (2.1) | 2 (3.0) |
 Unknown | 1 (5.0) | 2 (4.3) | 3 (4.5) |
 Multiple | 0 | 1 (2.1) | 1 (1.5) |
 American Indian or Alaska Native/White | 0 | 1 (2.1) | 1 (1.5) |
Ethnicity, n (%) | Â | Â | Â |
 Hispanic or Latino | 13 (65.0) | 30 (63.8) | 43 (64.2) |
 Not Hispanic or Latino | 6 (30.0) | 14 (29.8) | 20 (29.9) |
 Not Reported | 1 (5.0) | 1 (2.1) | 2 (3.0) |
 Unknown | 0 | 2 (4.3) | 2 (3.0) |
Baseline weight (kg), mean (SD) | 88.9 (19.3) | 89.1 (19.7) | 89.1 (19.4) |
BMI (kg/m2), n(%) | Â | Â | Â |
 18.5 to < 25 | 2 (10.0) | 6 (12.8) | 8 (11.9) |
 25 to < 30 | 8 (40.0) | 20 (42.6) | 28 (41.8) |
 30 to < 40 | 9 (45.0) | 13 (27.7) | 22 (32.8) |
 ≥ 40 | 1 (5.0) | 8 (17.0) | 9 (13.4) |
Medical history group, n (%) | Â | Â | Â |
 Obesity | 10 (50.0) | 22 (46.8) | 32 (47.8) |
 Diabetes | 4 (20.0) | 17 (36.2) | 21 (31.3) |
 Respiratory disorders | 4 (20.0) | 8 (17.0) | 12 (17.9) |
 Renal disorders | 1 (5.0) | 7 (14.9) | 8 (11.9) |
 Cardiovascular disorders | 2 (10.0) | 4 (8.5) | 6 (9.0) |
 Autoimmune disorders | 2 (10.0) | 1 (2.1) | 3 (4.5) |
Days since COVID-19 diagnosis, mean (SD) | 7.7 (3.8) | 8.0 (4.9) | 7.9 (4.5) |
Days since COVID-19 hospitalisation, mean (SD) | 3.1 (2.8) | 2.8 (1.5) | 2.9 (2.0) |
ICU admission at baseline | Â | Â | Â |
 No / Yes | 17 (85.0)/ 3 (15.0) | 46 (97.9)/ 1 (2.1) | 63 (94.0)/ 4 (6.0) |
Baseline CRP (mg/L), mean (SD) | 133.5 (88.4) | 105.6 (67.2) | 113.9 (74.6) |
Baseline Ferritin (ug/L), mean (SD)* | 1411.1 (1086.9) | 2389.0 (8126.6) | 2089.3 (6784.3) |
Baseline LDH (IU/L), mean (SD)* | 338.4 (116.0) | 350.8 (111.4) | 347.0 (112.0) |
Baseline SpO2/FiO2(ratio), mean (SD) | 294.1 (55.3) | 296.8 (62.9) | 296.0 (60.3) |
Oxygen therapy at baseline | Â | Â | Â |
 Nasal cannula | 13 (65.0) | 25 (53.2) | 38 (56.7) |
 Simple face mask | 6 (30.0) | 17 (36.2) | 23 (34.3) |
 Non-rebreather face mask | 0 | 1 (2.1) | 1 (1.5) |
 High-flow nasal cannula | 1 (5.0) | 1 (2.1) | 2 (3.0) |
 Non-invasive ventilation | 0 | 1 (2.1) | 1 (1.5) |
 Ambient | 0 | 2 (4.3) | 2 (3.0) |
Steroid treatment | Â | Â | Â |
 Dexamethasone | 13 (65.0) | 29 (61.7) | 42 (62.7) |
 Prednisone | 0 | 4 (8.5) | 4 (6.0) |
 Methylprednisolone | 1 (5.0) | 1 (2.1) | 2 (3.0) |